This article has been updated to clarify that the test has not been cleared for use in a point-of-care setting.

NEW YORK (GenomeWeb News) – Canadian molecular diagnostics developer Spartan Bioscience said today that the US Food and Drug Administration has granted 510(k) clearance to the Spartan RX CYP2C19 assay.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.